Data and Code for: Reference Pricing as a Deterrent to Entry: Evidence from the European Pharmaceutical Market
Principal Investigator(s): View help for Principal Investigator(s) Luca Maini, University of North Carolina at Chapel Hill; Fabio Pammolli, Politecnico di Milano
Version: View help for Version V1
Name | File Type | Size | Last Modified |
---|---|---|---|
Code Repository for upload | 06/07/2022 09:18:AM |
Project Citation:
Maini, Luca, and Pammolli, Fabio. Data and Code for: Reference Pricing as a Deterrent to Entry: Evidence from the European Pharmaceutical Market. Nashville, TN: American Economic Association [publisher], 2023. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2023-04-14. https://doi.org/10.3886/E160781V1
Project Description
Summary:
View help for Summary
External reference pricing (ERP), the practice of benchmarking domestic drug prices to foreign prices, generates an incentive for firms to withhold products from low-income countries. Using a novel moment inequality approach, we estimate a structural model to measure how ERP policies affect access to innovative drugs across Europe. We find that ERP increases entry delays in eight low-income European countries by up to one year per drug. The European Union could remove these delays without replacing ERP by compensating firms through lump-sum transfers at the cost of around 18 million euros per drug.
Scope of Project
Subject Terms:
View help for Subject Terms
prescription drugs;
moment inequality;
reference pricing
JEL Classification:
View help for JEL Classification
I11 Analysis of Health Care Markets
L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
I11 Analysis of Health Care Markets
L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
Geographic Coverage:
View help for Geographic Coverage
Europe
Time Period(s):
View help for Time Period(s)
2002 – 2012
Universe:
View help for Universe
Prescription drugs sold in Europe from 2002 to 2012
Data Type(s):
View help for Data Type(s)
aggregate data
Methodology
Data Source:
View help for Data Source
IMS MIDAS
Unit(s) of Observation:
View help for Unit(s) of Observation
Drug, Country, Year
Related Publications
Published Versions
Report a Problem
Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.
This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.